Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Partruvix (pamiparib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

BeOne Medicines

Drug class:

PARP inhibitor

Related drugs:

BRCA1 mutation	Fallopian Tube Cancer	BRCA1 mutation	Fallopian Tube Cancer	pamiparib Sensitive: A1 - Approval pamiparib Sensitive : A1	pamiparib Sensitive: A1 - Approval pamiparib Sensitive : A1
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	pamiparib Sensitive: A1 - Approval pamiparib Sensitive : A1	pamiparib Sensitive: A1 - Approval pamiparib Sensitive : A1
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	pamiparib Sensitive: A1 - Approval pamiparib Sensitive : A1	pamiparib Sensitive: A1 - Approval pamiparib Sensitive : A1
BRCA2 mutation	Peritoneal Cancer	BRCA2 mutation	Peritoneal Cancer	pamiparib Sensitive: A1 - Approval pamiparib Sensitive : A1	pamiparib Sensitive: A1 - Approval pamiparib Sensitive : A1
BRCA1 mutation	Peritoneal Cancer	BRCA1 mutation	Peritoneal Cancer	pamiparib Sensitive: A1 - Approval pamiparib Sensitive : A1	pamiparib Sensitive: A1 - Approval pamiparib Sensitive : A1
BRCA2 mutation	Fallopian Tube Cancer	BRCA2 mutation	Fallopian Tube Cancer	pamiparib Sensitive: A1 - Approval pamiparib Sensitive : A1	pamiparib Sensitive: A1 - Approval pamiparib Sensitive : A1
BRCA2 mutation	Triple Negative Breast Cancer	BRCA2 mutation	Triple Negative Breast Cancer	pamiparib Sensitive: C1 - Off-label pamiparib Sensitive : C1	pamiparib Sensitive: C1 - Off-label pamiparib Sensitive : C1
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	pamiparib Sensitive: C1 - Off-label pamiparib Sensitive : C1	pamiparib Sensitive: C1 - Off-label pamiparib Sensitive : C1
BRCA1 mutation	Triple Negative Breast Cancer	BRCA1 mutation	Triple Negative Breast Cancer	tislelizumab-jsgr + pamiparib Sensitive: C2 – Inclusion Criteria tislelizumab-jsgr + pamiparib Sensitive : C2	tislelizumab-jsgr + pamiparib Sensitive: C2 – Inclusion Criteria tislelizumab-jsgr + pamiparib Sensitive : C2
IDH2 mutation	Glioma	IDH2 mutation	Glioma	pamiparib Sensitive: C2 – Inclusion Criteria pamiparib Sensitive : C2	pamiparib Sensitive: C2 – Inclusion Criteria pamiparib Sensitive : C2
HRD	Ovarian Cancer	HRD	Ovarian Cancer	tislelizumab-jsgr + pamiparib Sensitive: C2 – Inclusion Criteria tislelizumab-jsgr + pamiparib Sensitive : C2	tislelizumab-jsgr + pamiparib Sensitive: C2 – Inclusion Criteria tislelizumab-jsgr + pamiparib Sensitive : C2
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	tislelizumab-jsgr + pamiparib Sensitive: C2 – Inclusion Criteria tislelizumab-jsgr + pamiparib Sensitive : C2	tislelizumab-jsgr + pamiparib Sensitive: C2 – Inclusion Criteria tislelizumab-jsgr + pamiparib Sensitive : C2